Polyclonal antibody TriTAb

Drug Profile

Polyclonal antibody TriTAb

Alternative Names: Polyclonal antibody TriTAb - Protherics; TriTAb

Latest Information Update: 09 Oct 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Protherics
  • Class Antidotes; Polyclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Poisoning

Most Recent Events

  • 09 Oct 2001 Discontinued-II for Poisoning in USA (Unknown route)
  • 19 Dec 2000 Protherics have reaquired the distribution rights of TriTab from Altana in the USA
  • 18 Oct 1999 Therapeutic Antibodies has merged with Proteus International to form Protherics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top